Scientists Identify New Epigenetic Approach to Target Colorectal Cancer
Researchers from the Johns Hopkins Kimmel Cancer Center and the Chinese Academy of Sciences have developed a novel drug strategy against colorectal cancer. In the new study, a little-known mouse protein was found to disrupt cancer-causing chemical changes to genes associated with human colorectal cancer cells. The mouse version of the protein, called STELLA, disrupted a key epigenetic factor and impaired tumor growth better than the protein’s human version. By pinpointing the amino acids (building blocks of a protein) responsible for the difference in activity, the research team developed and tested a drug strategy using those amino acids to treat colorectal cancer.
LEARN MORE
SEE ALL NEWS
Recent Posts
5 Healthy Habits That Help During Cancer Treatment
Understanding Mammogram Results
A 19-Year Fight Against Prostate Cancer Brings Man to Johns Hopkins Medicine
Scientists Advance Efforts to Create ‘Virtual Cell Lab’ As Testing Ground for Future Research with Live Cells
Ultra-Processed Foods: Q&A with 2 Dietitians
Radiation Therapy Overcomes Immunotherapy Resistance in Some Cancers
‘Power Surges’ on Cancer Cell Membranes May Fuel Progression of Disease
New Cancer Target Discovered
How surgeons build a new bladder for cancer patients like Deion Sanders